The same trend was seen in a 2021 study published in The New England Journal of Medicine
At the time of the announcement, Novo Nordisks executive vice president of US operations and global business development and president of Novo Nordisk Inc
The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease
About half of GLP-1 users say these drugs were difficult for them to afford, according to KFF polling
SGLT2 inhibitors are one of the recommended "add-on" therapies to metformin in the current ADA diabetes mellitus type 2 guidelines (alongside sulfonylureas, TZDs, DPP-4 inhibitors, GLP-1 agonists, or insulin) and the guidelines make no preference for any particular class, leaving it to patient-specific factors
These companies will need to understand how their demand may be impacted in the future, which part of their markets will be most affected, how their portfolio could evolve to mitigate the impact and how they can establish themselves as complementary to GLP-1RAs